Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of VB6-845 and to evaluate the safety and tolerability of VB6-845 when administered as a monotherapy IV infusion to patients with advanced solid tumour of epithelial origin.

Timeline

Start

2007-05

Primary completion

2008-04

Completion

2008-04

Outcome

Outcome not reported

Stopped: “Corporate reasons unrelated to safety and efficacy”

Drugs

Indications